DGAP-News: Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
(firmenpresse) - DGAP-News: Epigenomics AG / Key word(s): Miscellaneous
Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9
Testing by French Insurance Provider
12.12.2013 / 08:45
---------------------------------------------------------------------
Berlin, Germany, and U.S.A., December 12, 2013 - Epigenomics AG (Frankfurt
Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular
diagnostics company, today announced that MACSF (Mutuelle d'Assurance du
Corps de Sante?Français), the leading French supplementary insurance
provider for the medical community, will provide the blood-based Septin9
test for the early detection of colorectal cancer (CRC) as part of their
additional health insurance program. MACSF will reimburse EUR 50 on what
its policy holders pay for undergoing Septin9 testing.
MACSF offers about 800.000 policy holders from the medical community and
their families, such as doctors from the private and public sector, other
medical or paramedical workers including medical students an additional
health insurance, called 'Mutuelle'. After Swiss Life announced to provide
Septin9 as part of its preventive health program in July 2012, MACSF is the
second healthcare provider in France and the first 'Mutuelle' to reimburse
blood-based colorectal cancer screening.
Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented: 'We are extremely
pleased to experience this growing support by French insurance providers.
The fact that also MACSF now offers blood-based Septin9 tests to its
customers shows the importance of an alternative convenient and
non-invasive screening method. And, as their policy holders originate
primarily from the medical community, we also hope to raise awareness and
convince doctors of our Septin9-based test Epi proColon(R), so that they
increasingly recommend it to their patients'.
- Ends -
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is in development for the U.S.A and China. The Company's technology and
products have been validated through multiple partnerships with leading
global diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
About MACSF
MACSF Group (Mutuelle d'Assurance du Corps de Sante?Français) is for over
75 years the leading insurance provider for healthcare professionals in
France. Its mission is to provide supplementary insurance services for
private or work-related risks for its members working in the private or
public healthcare space.
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel +49 (0) 30 24345 386
ir(at)epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr(at)epigenomics.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
End of Corporate News
---------------------------------------------------------------------
12.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir(at)epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
244429 12.12.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.12.2013 - 08:45 Uhr
Sprache: Deutsch
News-ID 323687
Anzahl Zeichen: 4305
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 299 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider"
steht unter der journalistisch-redaktionellen Verantwortung von
Epigenomics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
